Discovery of how colorectal cancer drug works will help more patients
Salk scientists identified the mechanism by which cetuximab benefits colorectal cancer patients harboring the KRAS G13D mutation.
Salk scientists combined computational biology and experimental assays to uncover the reason why colorectal cancer tumors with the KRAS G13D mutation respond to the cetuximab EGFR‑blocking antibody – revealing that robust neurofibromin activity is required to control wild‑type KRAS, allowing cetuximab to inhibit growth of the mutant tumors.
Deciphering this mechanism provides a clear biomarker (KRAS G13D mutation) that enables clinicians to prescribe cetuximab to eligible colorectal cancer patients, potentially benefiting up to 10,000 patients annually.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics